Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

DMAC Relative to the S&P 500

DMAC Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the DiaMedica Therapeutics Inc. (NASD:DMAC) seasonal charts above shows that a Buy Date of January 29 and a Sell Date of June 20 has resulted in a geometric average return of 36.96% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 68.84% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

To download DMAC seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: DMAC